

[Retired Compendial Notices Prior to 2010](#)

- [<1> Proposed Revisions to the Labeling on Ferrules and Cap Overseals Section of General Chapter <1> Injections](#) (posted 24–Nov–2009)
- [<1> Injections: Notice of Intent to Revise](#) (posted 29–Jul–2009)
- [<1> Injections—USP Announcement on Labeling on Ferrules and Cap Overseals Section](#) (posted 08–May–2009)
- [<1> First Supplement to *USP 31–NF 26* includes an incorrect General Chapter: <1> Injections](#) (posted 07–Apr–2008)
- [<3> and <725> Topical and Transdermal Products—USP Forwards Proposed General Chapters on Topical and Transdermal Drug Products](#) (posted 29–May–2009)
- [<55> Second Supplement to *USP 31–NF 26* Online and CD includes an incorrect version of USP General Chapter <55> Biological](#) (posted 23–Jul–2008)
- [<61> and <62>: First Supplement *USP 31–NF 26* included three errors in USP General Chapters <61> and <62>](#) (posted 15–Aug–2008)
- [<232> <233> <1232>: Metal Impurities Advisory Panel Recommendations to the General Chapters Expert Committee](#) (posted 02–Jun–2009)
- [<381> Elastomeric Closures for Injections—Error in *USP 32–NF 27* Publication Dates](#) (posted 03–Dec–2008)
- [<467> Residual Solvents/Organic Volatile Impurities](#) (posted 15–Jun–2007)
- [<467> Frequently Asked Questions about <467> Residual Solvents](#)
- [<643> Total Organic Carbon Comment Period Extension](#) (posted 17–Oct–2007)
- [<671> Containers—Performance Testing: Notice of Intent to Revise](#) (posted 1–Dec–2007)
- [<711> Dissolution: Notice of Intent to Revise](#) (posted 11–Mar–2008)
- [<725> and <3> Topical and Transdermal Products—USP Forwards Proposed General Chapters on Topical and Transdermal Drug Products](#) (posted 29–May–2009)
- [<797> Errata Corrected in Revised General Chapter <797>](#) (posted 28–Jan–2008)
- [<905> Uniformity of Dosage Units](#) (posted 20–Apr–2007)
- [<1121> Nomenclature: Monograph Naming Policy for Salt Drug Substances in Drug Products and Compounded Preparations](#) (posted 04–Jun–2007; official 01–May–2013)
- [<1151> Pharmaceutical Dosage Forms](#) (posted 06–Oct–2009)
- [Acitretin Capsules](#) (posted 22–Jul–2009)
- [Alendronate Sodium Tablets: Notice of Intent to Revise](#) (posted 01–Feb–2008)
- [Cephalexin Monographs](#) (posted 07–Dec–2009; revised 30–Jun–2010)
- [Changes to the Dissolution Performance Verification Test](#) (posted 20–Nov–2009)
- [Coordination of Official New Monographs, Revisions, and USP Reference Standards](#) (posted 20–Feb–2006)
- [Coordination of PF Submissions and New USP Reference Standards](#) (posted 03–Apr–2006)
- [Correction to Pharmacopeial Forum 34\(2\)](#) (posted 07–Mar–2008)
- [Estradiol Vaginal Inserts](#) (posted 07–Dec–2009)
- [Galantamine Tablets: Notice of Intent to Revise \(Reposted\)](#) (posted 12–Jun–2009)
- [Galantamine Tablets](#) (posted 01–Aug–2008)
- [Green Tea Cautionary Labeling Update](#) (posted 10–Apr–2009)
- [Heparin: Notice of Heparin Stage 2 Interim Revision Announcements](#) (posted 24–Jun–2009)
- [Heparin and Enoxaparin Monographs: Stage 2 Web Postings Supersede Printed Monographs in *USP 33–NF 28*](#) (posted 22–Dec–2009)
- [Levalbuterol Hydrochloride](#) (posted 29–May–2009)
- [Levothyroxine Sodium Tablets](#) (posted 29–Aug–2008; official 03–Oct–2009)
- [Metal Impurities Advisory Panel Recommendations to the General Chapters Expert Committee](#) (posted 02–Jun–2009)
- [Missing Page Numbers in Auxiliary Information from Eight Chapters](#) (posted 10–Sep–2008)
- [Modafinil](#) (posted 19–Jun–2009)
- [Modafinil Tablets](#) (posted 19–Jun–2009)
- [Nefazodone Hydrochloride](#) (posted 20–Mar–2009)
- [New USP Reference Standards](#) (posted 07–Mar–2007)
- [Prospective Harmonization](#) (posted 09–Nov–2009)
- [Recent Modifications to the USP Standards–Setting Process](#) (posted 17–Jul–2007)
- [Revision to USP Pending Monographs Guideline](#) (posted 09–Nov–2009)
- [Six-Month Implementation Guideline](#) (posted 09–Nov–2009)

- [Sodium Fluoride and Acidulated Phosphate Topical Solution: Notice of Intent to Revise](#) (posted 07–Mar–2007)
- [Tamsulosin Hydrochloride Capsules: Notice of Intent to Revise](#) (posted 08–Apr–2009)
- [Tazobactam: Notice of Intent to Revise](#) (posted 29–Feb–2008)
- [USP 32–NF 27 Commentary Amended](#) (posted 19–Mar–2009)
- [USP 33–NF 28 Errata](#) (posted 17–Nov–09)
- [USP Invites Public Comments on its Dietary Supplement Safety Review Process](#) (posted 03–Dec–2008)
- [USP Performance Test and the Dissolution Procedure Statement](#) (posted 24–Oct–2006)
- [USP Releases Improved Packaging for Salicylic Acid Calibrator Tablets](#) (posted 19–Oct–2005)
- [USP Revises its Request for Revision Guideline](#) (posted 24–July–2009)
- [USP Statement on Prednisone Tablets: Notice of Change in Performance](#) (posted 10–Oct–2007)